Payment overview · 2025
General Payments
$252.00
12 reported records · 7 companies
Healthcare provider profile · identity verified
Stacie Nelson, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care · TEMPLE, TX · NPI 1164518502
Verified facts
What the public records show
CMS Open Payments records show Stacie Nelson, NP received $252.00 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.17 | 23.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.38 | 18.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.79 | 15.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.60 | 15.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.16 | 11.6% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.96 | 9.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.94 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.00 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $58.17 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.79 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $31.66 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 67 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
153 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 513 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 452 | 121 |
| Lisinopril | Lisinopril | 310 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 285 | 82 |
| Losartan Potassium | Losartan Potassium | 257 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 246 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 78 |
| Omeprazole | Omeprazole | 236 | 71 |
| Gabapentin | Gabapentin | 233 | 60 |
| Famotidine | Famotidine | 206 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 44 |
| Simvastatin | Simvastatin | 199 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 50 |
| Trazodone Hcl | Trazodone Hcl | 186 | 49 |
| Montelukast Sodium | Montelukast Sodium | 181 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 45 |
| Alprazolam | Alprazolam | 169 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 47 |
| Eliquis | Apixaban | 153 | 26 |
| Metformin Hcl | Metformin Hcl | 152 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 139 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 36 |
| Furosemide | Furosemide | 134 | 45 |
| Carvedilol | Carvedilol | 126 | 39 |
| Alendronate Sodium | Alendronate Sodium | 119 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 26 |
| Allopurinol | Allopurinol | 113 | 27 |
| Ozempic | Semaglutide | 111 | 24 |
| Meloxicam | Meloxicam | 110 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 22 |
| Potassium Chloride | Potassium Chloride | 96 | 34 |
| Methylprednisolone | Methylprednisolone | 92 | 81 |
| Sertraline Hcl | Sertraline Hcl | 86 | 22 |
| Ezetimibe | Ezetimibe | 85 | 27 |
| Finasteride | Finasteride | 85 | 21 |
| Donepezil Hcl | Donepezil Hcl | 84 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 24 |
| Warfarin Sodium | Warfarin Sodium | 75 | 11 |
| Azithromycin | Azithromycin | 73 | 66 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | 15 |
| Tramadol Hcl | Tramadol Hcl | 69 | 31 |
| Rybelsus | Semaglutide | 67 | 17 |
| Metformin Hcl Er | Metformin Hcl | 66 | 20 |
| Lorazepam | Lorazepam | 65 | 14 |
| Atenolol | Atenolol | 64 | 23 |
| Bupropion Xl | Bupropion Hcl | 64 | 13 |
| Buspirone Hcl | Buspirone Hcl | 63 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 14 |
| Valsartan | Valsartan | 62 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 16 |
| Clonazepam | Clonazepam | 59 | 11 |
| Glipizide | Glipizide | 59 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 17 |
| Ondansetron Odt | Ondansetron | 57 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 15 |
| Glipizide Er | Glipizide | 56 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 12 |
| Xarelto | Rivaroxaban | 56 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 14 |
| Memantine Hcl | Memantine Hcl | 52 | 14 |
| Prednisone | Prednisone | 50 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 15 |
| Mirtazapine | Mirtazapine | 49 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 40 |
| Farxiga | Dapagliflozin Propanediol | 48 | 16 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Temazepam | Temazepam | 46 | 12 |
| Cefdinir | Cefdinir | 45 | 41 |
| Pregabalin | Pregabalin | 45 | 13 |
| Clonidine Hcl | Clonidine Hcl | 44 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Nystatin | Nystatin | 43 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Baclofen | Baclofen | 41 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | 11 |
| Celecoxib | Celecoxib | 40 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 14 |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Methocarbamol | Methocarbamol | 38 | 18 |
| Promethazine Hcl | Promethazine Hcl | 38 | 19 |
| Cefuroxime | Cefuroxime Axetil | 36 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 12 |
| Estradiol | Estradiol | 36 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | 12 |
| Armour Thyroid | Thyroid,pork | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 21 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Ursodiol | Ursodiol | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Dexamethasone | Dexamethasone | 21 | 17 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 11 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $252.00 · 12 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, GVOKE HYPOPEN, NURTEC ODT, Ozempic, Rybelsus, VELSIPITY, VENASEAL, VRAYLAR, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error